Corbus’ Lenabasum Fails Phase III Trial for Systemic SclerosisArthritis & Rheumatology, Business, Clinical Trials, Data, Primary Endpoints, R&D, Shares, Small Molecules, Systemic Sclerosis (SSc)Norwood, Massachusetts-based Corbus Pharmaceuticals’ shares plunged 77% at news the company’s lenabasum failed to hit the primary endpoint in the Phase III RESOLVE-1 trial of diffuse cutaneous systemic sclerosis (SSc). Read more September 8, 2020/by BioSpace https://www.pharmalive.com/wp-content/uploads/2020/09/Corbus-Lenabasum-Fails-Phase-III-Trial-for-Systemic-Sclerosis-BioSpace-9-8-20.jpeg 350 625 BioSpace https://www.pharmalive.com/wp-content/uploads/2020/01/Pharmalive_4c-300x37.png BioSpace2020-09-08 11:45:172020-09-08 18:19:01Corbus’ Lenabasum Fails Phase III Trial for Systemic Sclerosis